BA-010 - Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
Publication/Presentation Date
6-2017
Volume
28
Issue
3
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article
COinS